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ABSTRACT 
7KH LQWULQVLFDOO\ GLVRUGHUHG DQG DP\ORLGRJHQLF SURWHLQ Į-synuclein (AS) has been linked to several 
neurodegenerative states, LQFOXGLQJ3DUNLQVRQ¶VGLVHDVHHere, nano-electrospray-ionization mass spec-
trometry (nano-ESI-MS), ion mobility (IM), and native top-down electron transfer dissociation (ETD) 
techniques are employed to study AS interaction with small molecules known to modulate its aggrega-
tion, such as epigallocatechin-3-gallate (EGCG) and dopamine (DA). The complexes formed by the 
two ligands under identical conditions reveal peculiar differences. While EGCG engages AS in com-
pact conformations, DA preferentially binds to the protein in partially extended conformations. The 
two ligands also have different effects on AS structure as assessed by IM, with EGCG leading to pro-
tein compaction and DA to its extension. Native top-down ETD on the protein-ligand complexes shows 
how the different observed modes of binding of the two ligands could be related  to their known oppo-
site effects on AS aggregation. The results also show that the protein can bind either ligand in the ab-
sence of any covalent modifications, such as e.g. oxidation. 
 
 
KEYWORDS 
Mass spectrometry, ion mobility, electron transfer dissociation, non-FRYDOHQWFRPSOH[HV3DUNLQVRQ¶V
disease, aggregation inhibitors, amyloid protein, intrinsically disordered protein.  
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INTRODUCTION 
Amyloid aggregation of the intrinsically disordered protein (IDP) Į-synuclein (AS) has been implicated 
in several neurodegenerative disorders, called synucleinopathiesLQFOXGLQJ3DUNLQVRQ¶V'LVHDVH3'1. 
In particular, AS is the major component of the Lewy Bodies (LB) from post-mortem brains of PD pa-
tients. Duplication, triplication and point mutations in the AS gene are associated with familial PD. AS 
is a highly abundant neuronal protein of 140 amino acids with an average molecular weight of 14460.1 
Da. It exists in solution as a highly dynamic and heterogeneous conformational ensemble. The equilib-
rium between extended and partially folded conformations can be shifted by environmental factors and 
ligand binding. Solution pH, temperature, crowding agents, membranes, metal ions and interacting pro-
teins have been shown to impact on AS conformational states1. Selective stabilization of distinct con-
formers is thought to elicit formation of supramolecular structures with different toxicities and 
amyloidogenic potentials1. 
Several classes of compounds, such as dyes, flavonoids, polyphenols and catecholamines, have been 
shown to inhibit AS fibrillation. Such inhibitors have attracted attention for the development of new 
drugs against amyloidoses2,3. A promising anti-amyloidogenic compound is the antioxidant molecule 
epigallocatechin-3-gallate (EGCG), the major green tea polyphenol which displays neuroprotective and 
anticancerogenic effects in cellular and animal models4,5. EGCG redirects AS aggregation into off-
pathway, non-toxic, SDS-resistant, spherical and nanostructured oligomers of ~20-nm diameter6. 
Noteworthy, EGCG has been shown to affect in a similar way the aggregation pathway of several 
DP\ORLGRJHQLFSURWHLQVVXFKDV$ȕ6, huntingtin7 and ataxin-38. Moreover, EGCG is capable of remod-
eling mature AS amyloid fibrils into smaller, non-toxic, amorphous aggregates9. Dopamine (DA) is 
among the most intensively studied modulators of AS-aggregation. A large amount of data substantiate 
the crucial role of DA and its oxidation products in PD10, which is characterized by degeneration of do-
paminergic neurons. In vivo, DA is synthesized in the cytosol of dopaminergic neurons where it is 
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stored in the monoaminergic vesicles and released in the intersynaptic space to interact with its physio-
logical receptors10-12. DA has been shown to inhibit AS fibrillation and to promote aggregation into 
SDS-resistant oligomers11. It has been proposed that this process depends on DA oxidation but not on 
AS oxidation13. Other authors14 suggested that the main mechanism of DA-dependent AS 
oligomerization is related to methionine oxidation. Moreover, it has been found that only a small frac-
tion (5-10%) of AS is covalently binding DA oxidation products in the final aggregates obtained in 
vitro in the presence of the ligand, suggesting that DA and its oxidation products mainly act by non-
covalent interactions15. DA-induced AS-oligomers have been associated to relatively low toxicity16. 
However, other works point to a well-defined toxicity with impairment of chaperone-mediated autoph-
agy17 and SNARE-mediated vesicle docking18. Electron micrographs show rod-shaped, nanostructured 
oligomers ׽37 nm long18. It has been put forward that DA could serve as a lead molecular structure for 
the design of improved modulators19. 
The interaction of EGCG and DA with AS has been investigated by several biophysical methods6,9,20-24, 
including native mass spectrometry21-23. Native mass spectrometry relies on gentle transfer of proteins 
and their complexes from solution into the gas phase of the mass spectrometer, without major structural 
rearrangements or disruption of non-covalent interactions25-28. As such it is especially useful for detect-
ing non-covalent ligand binding29,30. However, a direct comparison of the complexes formed by AS 
with these two ligands has not been previously reported in the literature. 
To better understand the molecular action of modulators of AS aggregation, the early stage of AS mon-
omer interaction with EGCG and DA is investigated here by native MS, ion mobility, and native top-
down electron transfer dissociation (ETD) in order to conjugate binding analysis to structural investiga-
tion. The two ligands display opposite conformational selectivity and distinct effects on AS compact-
ness. 
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EXPERIMENTAL SECTION 
Materials and sample preparation. See Supporting information.  
Nano-ESI mass spectrometry. Mass spectrometry measurements were performed at a final protein 
concentration of 20 µM in 10 mM ammonium acetate pH 7.4. MS spectra were collected upon 10-min 
incubation of the protein-ligand mixtures at room temperature. 
Nano-ESI-MS spectra were generally collected in positive-ion mode, using a hybrid quadrupole-time-
of-flight mass spectrometer (QSTAR-Elite, Biosystems, Foster City, CA) equipped with a nano-ESI 
sample source. See the Supporting information for details. 
 
Ion mobility. Ion mobility mass spectrometry (IM-MS) was performed on a Synapt G2 HDMS (Wa-
ters, Manchester, UK) using nano-ESI with homemade gold-coated borosilicate capillaries. Important 
settings were: 1.2-1.6 kV capillary voltage, 25 V sampling cone, 1 V extraction cone, 4 V trap CE, 0 V 
transfer CE, and 42 V trap bias. Gas pressures used throughout the instrument were 2.9 mbar, 2.4 E-2 
mbar, 3.1 mbar and 2.6 E-2 mbar for the source, trap cell, IM cell and transfer cell respectively. Spectra 
were analyzed using Masslynx version 4.1 (Waters, Manchester, UK) and Driftscope v2.3 (Waters, 
Manchester, UK). Aggregate intensities per peak series (conformation) were extracted after a multiple 
Gauss curve fitting of the arrival time distributions based on the observed number of conformations. To 
identify relative intensities, the area under the fitted Gaussian curve of a single conformation was com-
pared to the summed areas of all conformations.   
 
Electron transfer dissociation. Native top-down MS experiments were performed using a Synapt G2 
HDMS with ETD option. Important voltages were: sampling cone 25 V, extraction cone 1 V, trap colli-
sion energy 4 V, transfer collision energy 0.5-1 V and trap DC bias 40 V. Selected precursor ions (AS, 
AS+1DA and AS+1EGCG, all 12+ charge states for comparison) were mass-selected individually us-
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ing the 32k quadrupole and underwent an ion-ion ETD reaction with 1,4 dicyanobenzene reagent in the 
trap T-wave (at ~5x10-2 mbar He) of the instrument. ETD settings used were a scan time interval of 1 s 
and a reagent refill time of 0.1 s. The wave velocity in the trap cell, where the ETD fragmentation takes 
place, was 300 m/s with a wave height of 0.4 V. ETD fragments were assigned manually. 
 
RESULTS AND DISCUSSION 
EGCG binding is observed preferentially with AS in compact conformations. The nano-ESI-MS 
spectrum of AS in the absence of the ligands (Fig. 1A) displays the typical multimodal charge-state dis-
tribution (CSD), with maxima at 8+ and 15+. Protein charge states in ESI-MS reflect the degree of 
structural compactness. Compact structures result in lower charge states, a feature that has been related 
to smaller solvent accessible surface area (SASA) and lower gas-phase basicity31. In agreement with 
previous reports32,33, these results suggest coexistence of different conformational states for AS in solu-
tion at neutral pH with collapsed and extended conformers corresponding to the low- and high-charge 
envelope, respectively. Gaussian fitting of the CSD suggests the presence of a total of four components 
(Fig. S-1), which represent conformers of progressively increasing compactness as net charge decreas-
es32,33. Small, dimer-specific peaks are also detectable (Fig. 1)32. 
Titration with EGCG leads to the appearance of protein-ligand complexes with up to 1:3 stoichiometry 
(Fig. 1A-D). The masses of the complexes in the mass-deconvoluted spectra (Fig. 1D) match within 2 
Da tolerance with the theoretical values. The complexes can be dissociated by collisional activation, 
confirming the identity of the ligand and the non-covalent nature of the interaction (Fig. S-2 and S-3). 
Therefore, no protein or ligand oxidation, or other kind of covalent modification, is required for the ini-
tial establishment of AS-EGCG complexes. 
It can be noted (Fig. 1B, 1C) that EGCG complexes are observed with higher relative intensity at low 
protein charge states, suggesting that this ligand either binds preferentially to AS in compact conforma-
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tions or shifts the conformational equilibrium towards the compact state upon binding, or both. CSD 
analysis also shows that the low-charge component is progressively lost during the titration. This trend 
likely reflects selective depletion by aggregation into species that escape detection. Consistently, the 
total protein counts display a general trend of decrease along the titration, on the background of the ex-
perimental variability among runs (Fig. S-4). Thus, the net effect of these two phenomena is a minor 
shift of the average charge state along the titration (less than one unit). 
To better illustrate the dependence of apparent binding affinity on charge state, Fig. 1E reports the total 
signal intensity of the AS-EGCG complexes (regardless of stoichiometry), relative to the signal inten-
sity of the free protein, for the 8+ and 15+ charge states, representing the two maxima of the bimodal 
distribution. The results show higher fractions of bound protein for the 8+ ions (compact state) 
throughout the titration. 
The signals of the free and bound protein can be extracted from the raw data and visualized separately 
for better comparison. The results are shown in Fig. S-5 for an intermediate point of the titration. It can 
be noted that the CSD of the bound form is shifted towards lower charge states relative to the CSD of 
the free protein, with a shift in average charge state from 14.1 to 13.1. Curve fitting performed selec-
tively on the signals of either free or bound AS, in the presence of 80 µM EGCG, indicates a significant 
accumulation of the low-charge components (8.4 and 10.9) upon ligand binding, at the expense of the 
intermediate component (14.3) (Fig. S-6). The same comparison performed by combining all the 
stoichiometries >1 give similar results (data not shown). Altogether these results hint at structural dif-
ferences in the conformational ensemble of free and EGCG-bound AS in solution, with increased aver-
age compactness of the bound protein. 
Previous work has shown that EGCG binds more strongly to unfolded rather than folded proteins6, con-
sistent with an interaction with the polypeptide backbone. However, within the AS conformational en-
semble, binding seems to involve preferentially compact species. These observations are not in conflict, 
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since the previously published analyses could not discriminate among different conformers of disor-
dered ensembles. We performed additional measurements employing mixtures of AS, EGCG, and cy-
tochrome c (CytC) as a reference protein to assess non-specific binding. As shown in Fig. S-7, CytC-
EGCG complexes were detected in the ternary mixtures at similar levels as AS-EGCG complexes. 
Thus, the control experiment with a reference protein reveals non-specific binding of this ligand. This 
result is not unexpected, since EGCG has been reported to interact with a very large number of 
folded34-40 and disordered41,42 proteins. In particular, disorder-to-order transitions upon EGCG binding 
have been observed for the human salivary proline-rich protein IB541 and the dephosphorylated form of 
ȕ-casein42. Moreover, EGCG has been shown to affect the aggregation pathway of several 
amyloidogenic proteins4,6-8. These studies also suggest that EGCG binds to the protein backbone, as 
well as to hydrophilic and hydrophobic side chains. The AS-EGCG interaction was also tested by nano-
ESI-MS in negative-ion mode (Fig. S-8). In the absence of the ligand, AS displays a multimodal 
charge-state distribution33, similar to positive-ion spectra. In the presence of the ligand, complexes are 
detected preferentially for the low-charge component (7- to 9-), resulting again in a shift of the CSD of 
the bound form towards lower charge states relative to the CSD of the free protein (Fig. S-8D). Also in 
this case, curve fitting performed selectively on the signals of either free or bound AS indicates a sig-
nificant accumulation of the low-charge components (7.3 and 10.3) at the expenses of the intermediate 
component (13.9) upon ligand binding (Fig. S-8E and F). These results indicate that the observed trend 
does not depend on instrument polarity. This is the expected result for interactions characterized by real 
conformational selectivity and/or induced conformational changes, making less likely that the observed 
bias is due to artifacts of the electrospray process. These data also suggest that the applied experimental 
conditions do not affect the main structural features of the protein ensemble and the protein-ligand 
complexes. 
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EGCG binding promotes AS compaction. The structural effects of EGCG binding were further in-
vestigated by IM-MS. Native IM-MS is a gas phase separation technique where ions are separated 
based on their mobility in a gas filled drift tube upon applying a low electric field43. Their mobility is 
influenced by their compactness, mass and charge and thus even coexisting conformations of a protein 
with identical mass and charge can be separated44,45. The conformers populating each charge state are 
separated and characterized by their rotationally averaged collisional cross section (CCS)46. The IM-
MS results are summarized in Fig. 2. 
Multiple conformers were detected for low and intermediate charge state (6+ to 12+). Fig. 2A shows 
the change in relative populations of the 8+ charge state (with more extended conformations having a 
larger CCS) per EGCG bound state. Binding of EGCG progressively enhances AS compaction, in-
creasing the relative amounts of the compact conformers as the number of EGCG molecules bound in-
creases. EGCG binding does not yield new conformations, but rather shifts the conformational ensem-
ble towards the two most compact states already present, although barely detectable, in the absence of 
the ligand. A comparison of the protein in the absence of ligand (³&´LQ)LJ. 2A and B) with the un-
ERXQGVWDWHLQWKHSUHVHQFHRIOLJDQG³´VKRZVODUJHO\the same conformational population, which is 
strong indication that no significant ligand loss occurs upon transfer from solution to the gas phase. 
Similar effects are observed for any of the charge states of AS displaying multiple conformations (Fig. 
S-9) independent of ionization mode (Fig. S-10). For charge states displaying only a single confor-
mation, but where EGCG binding is observed (13+ to 15+), no conformational change is detected. It 
should be noted that high charge states are generally not very informative in IM experiments46. 
For CytC, too, IM measurements reveal more compact conformations upon increasing numbers of 
EGCG bound (Fig. S-11). In conclusion, these and previously published results point to EGCG as a ge-
neric binder34-42 and modulator41,42 of protein structure. 
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The protective effect of EGCG against amyloidosis has been attributed to the formation of off-pathway 
protein oligomers that prevent fibrillation6. The here reported results suggest that formation of these 
off-pathway species is preceded by a compaction of AS monomers upon EGCG binding. Compact con-
formations might interfere with on-pathway fibrillation in different ways. The compact monomers 
themselves might not be able to bind to existing ȕ-sheet oligomers, thus preventing further elongation 
of proto-fibrils, and/or they could be sequestered into non-amyloidogenic, oligomeric structures6. 
 
DA binding is observed preferentially with AS in partially extended conformations. A typical AS 
titration with DA by nano-ESI-MS in positive-ion mode is shown in Fig. 3. The addition of the ligand 
leads to the appearance of AS:DA complexes, up to a 1:4 stoichiometry. The latter state however ap-
pears only at 6 mM DA concentrations and is only barely detectable (Fig. 3B). The identity of the lig-
and and the absence of covalent modifications have been confirmed by dissociation of the non-covalent 
complexes in MS/MS experiments (Fig. S-12). All the masses of the parent and product ions in the 
MS/MS spectra (Fig. 3B and S-12) match the theoretical values within 1.3 Da tolerance.  
Complexes are detected preferentially for the protein charge states 10+ to 17+ (Fig. 3A), corresponding 
to partially extended conformations of AS monomers (Fig. S-1). To better illustrate this trend, Fig. 3C 
reports the relative intensity of free and bound protein for the 8+ and 15+ charge states, as shown above 
for EGCG. The results show a strong bias in favor of the highly charged ions. These data are in agree-
ment with previous MS analyses of these complexes21,22. The extracted CSDs of the free and bound 
protein for an intermediate point of the titration are reported in Fig. S-13. The results show a shift to-
wards intermediate charge states for the bound form, with increasing intensity for the 12+ and 13+ ions 
and decreasing intensity for all the other charge states. The same comparison performed by combining 
all the stoichiometries >1 gives similar results (data not shown). Curve fitting performed selectively on 
the signals of either free or bound AS, in the presence of 200 µM DA, (Fig. S-14) indicates a signifi-
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cant accumulation of the intermediate component (13.4) at the expenses of the high- and low-charge 
components upon ligand binding (Fig. S-14). 
The results at 6 mM DA are compared with the occupancy profiles predicted by protein-ligand binding 
models with identical and independent interaction sites, assuming either a 1:3 or a 1:4 stoichiometry 
(Fig. 3D). The data fit the 1:3 model better, with some minor additional non-specific binding leading to 
the appearance of very small amounts of the 1:4 complex. These results suggest that AS contains three 
non-FRRSHUDWLYHELQGLQJVLWHVIRU'$7KHVDPHDQDO\VLVRIWKHGDWDREWDLQHGDWȝ0'$GRHVQRW
discriminate between the two alternative models (Fig. S-15). Ternary mixtures with CytC as a reference 
protein confirm that non-specific DA binding is negligible (Fig. S-16). Also in such mixtures (as ex-
pected) DA binding to AS was observed preferentially with partially extended conformations. 
Measurements in the negative-ion mode failed to detect AS-DA complexes, although free, deprotonat-
ed DA can be detected in the spectra (data not shown). Therefore, additional control experiments were 
performed by measurements in positive-ion mode. Tyrosine, which is structurally similar to DA but 
does not affect AS fibrillation13, was used as a negative control. Different from DA, tyrosine forms de-
tectable complexes only at mM concentrations. The data obtained with 1 mM DA or tyrosine are 
shown in Fig. S-16 for comparison, showing much stronger binding by DA. The free ligand concentra-
tions corresponding to 50% saturation 47 are 438.4 µM ± 90.8µM for DA and 3.51 mM ± 0.84 mM for 
Tyr. The value obtained for DA is of the same order of magnitude as the recently reported dissociation 
constant by isothermal titration calorimetry (285 µM)20, although quite a broad range of values are re-
ported in the literature24,48. Furthermore, Tyr binding does not induce changes in the CSD comparable 
to those observed with DA (Fig. S-17).  Thus, the evidence of a bias for intermediate charge states, de-
fined stoichiometry, and different responses to DA and tyrosine suggests that the observed complexes 
reflect, indeed, AS binding propensities characteristic of the solution phase, rather than adduct for-
mation induced by the electrospray conditions. The lack of complexes in negative-ion mode might be 
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due to enrichment of deprotonated DA inside the ESI droplets, which could in turn represent a poor lig-
and for AS19. 
 
DA binding promotes AS elongation. IM-MS was used to investigate structural effects of DA binding 
to AS. Similar to EGCG, DA binding affects the equilibrium among conformations present already in 
the free protein (Fig. 2C and D). With increasing numbers of DA bound, the 11+ charge state of AS 
becomes increasingly extended (Fig. 2C). Similar results are obtained for the 10+ and 12+ CS, which 
all display two coexisting conformations for unbound AS. From CS 13+ and higher, AS exists in a sin-
gle conformation in the gas phase, which does not change significantly upon DA binding (Fig. S-18).  
Given that DA is positively charged at neutral pH and likely binds as a protonated species to AS in pos-
itive-ion mode, it might be argued that the observed effect of DA on AS structure is due to electrostatic 
repulsions peculiar to the gas phase. However, it should be noted that CCS variations are detected here 
within a given charge state. Thus, comparison is performed always among ions with the same net 
charge, and the observed changes in drift time are interpreted as a specific structural effect, linked to 
the nature of the ligand. It could be also argued that the more extended conformers accumulating at in-
creasing DA loading derive from higher charge state(s) by loss of charged ligand molecule(s) and re-
tention of the conformation typical of the higher charge state. However, such a mechanism would be 
expected to produce the moUHH[WHQGHGFRQIRUPHUDOVRLQ WKH³HPSW\´SURWHLQ, by dissociation of the 
ligand from the 1:1 complex, which is not the case here. Furthermore, structures would be expected to 
rearrange upon charge reduction49. Recently, conformational studies on IDPs by ESI-MS and ESI-IM-
MS have been questioned50. In particular, the compact components frequently detected by these tech-
niques have been ascribed to the electrospray process itself. Multiple competing mechanisms for the re-
lease of the IDP from the droplet would cause the multiple overlapping CSDs which are often observed 
for IDPs. Interestingly, the effects reported here on the CSDs and CCSs of a single protein are ligand-
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specific and have opposite directions, making it unlikely that they merely reflect consequences of the 
electrospray mechanism. 
As dopaminergic neuron loss is a hallmark of PD and clinical symptoms can be alleviated by adminis-
tering L-dopa, the DA metabolism has been linked to AS aggregation. Our results suggest that at least 
the initial interaction between AS and DA is of a specific, noncovalent nature. In addition, there is no 
need for modification of AS or DA, such as oxidation of AS or conversion of DA to melanin or other 
oxidation products, to establish this interaction. Although these results do not rule out that such interac-
tions exist and can contribute to toxicity, the initial effect of dopamine binding seems to be elongation 
of AS monomers. Initial DA-dependent elongation of AS might well fit to a model where AS 
oligomerization is achieved through stacking of extended monomers without any end-to-end associa-
tions51, which are eventually cross-linked with DA-quinone/DA-melanin oxidation products. As such, 
DA binding might already prime AS for off-pathway oligomerization52. 
Correlating the structure remodeling by DA and EGCG with their binding modes. To assess 
whether we could correlate the structural remodeling effect of DA and EGCG to their modes of bind-
ing, we turned to ETD ligand footprinting on free AS as well as the DA- and EGCG-bound complexes. 
Top-down electron transfer dissociation (ETD) experiments are based on sequencing intact proteins 
with a radical-driven fragmentation method combined with mass spectrometry detection yielding in-
formation on the primary structure of the protein with amino acid resolution53,54. As ETD primarily 
cleaves the backbone of the protein, it maintains most non-covalent interactions, such as ligand binding 
or higher order protein structure when performed on native proteins55-57. As we have shown that both 
the DA and EGCG interactions are non-covalent, it is important to perform native top-down ETD to 
prevent disruption of these labile interactions and to accurately determine their binding sites.  The re-
sults of these experiments are summarized in Fig. 4 and show a reasonable sequence coverage for free 
AS (42 %), in line with previously observed fragmentation efficiency of AS58. Upon exposing the 1:1 
14 
 
 
non-covalent AS-ligand complexes to native ETD, we see a slight increase in sequence coverage (49% 
and 44% for DA and EGCG, respectively), which is caused by peptides that are ligand-bound. The DA 
binding site was located in the C-terminal amino acids 127MPSEE131. Indeed binding of DA to AS has 
been reported near the 125YEMPS129 region59, which overlaps with the binding site observed by top-
down ETD. The localization of M127 within this region is interesting as it might explain the mechanism 
by which DA prevents fibril formation and induces DA-dependent oligomerization. The localization of 
a well-defined binding site near this methionine would facilitate oxidation of M127, which in turn has 
been coined to be crucial for disruption of fibril formation by redirecting oligomerization of AS into 
off-pathway species14,52,60. The series of fragments from the 98DQLGKN103 stretch could confirm pre-
vious observations by molecular modelling that apart from binding the 125YEMPS129 region, DA also 
shows interactions with residues near the NAC domain of AS, thus promoting fragmentation in this re-
gion61. 
The fragmentation pattern for the AS-EGCG complex reveals partial binding and not well localized, as 
peptide fragments carrying EGCG were found across the protein sequence together with their unbound 
counterparts. These results strengthen the conclusions about non-specific binding of EGCG to the pep-
tide backbone. The absence of a well-defined binding site is interesting as it shows how an effective 
modulator of aggregation can utilize non-specific rather than specific binding. The ability of com-
pounds like EGCG that bind non-specifically but can direct the conformational ensemble in a specific 
direction might be a novel and potent method to affect structurally promiscuous drug targets.     
 
CONCLUSIONS 
This work shows for the first time that EGCG and DA have opposite structural effects on AS confor-
mational ensembles. This effect is consistently shown by CSD analysis, which is supposed to capture 
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the state of the protein at the time of leaving the solution, and by IM measurements, which depict struc-
tures in the gas phase.  
These findings help to rationalize the previously reported differences between the two ligands on AS 
aggregation (Fig. 5). Both DA and EGCG are known to stabilize AS oligomers. However, while DA-
induced oligomers display some toxicity on cultured cells16-18, EGCG-induced oligomers are non-
toxic6. The accumulation of compact or elongated protein-ligand complexes in the presence of the dif-
ferent ligands is likely at the basis of their distinct effects on AS aggregation mechanism. 
Preferential binding to specific conformers of amyloid proteins has recently been reported for inhibitors 
RIWKHILEULOODWLRQSDWKZD\RIȕ-microglobulin62 and amylin63. This study further underscores the po-
tential use of ESI-MS, ion mobility and native top-down ETD for the investigation of protein-inhibitor 
interactions and for drug screening64-66. The interplay among ligand-binding, oxidation, AS 
oligomerization and aggregation is still not completely understood. The data reported here indicate that 
covalent modifications of EGCG, DA, and AS are not required in order to establish interactions of the 
protein with the ligands and to induce structural changes in the protein. These results demonstrate the 
power of nano-ESI-IM-MS in investigating the mechanism of action of potential anti-fibrillogenic 
compounds, thanks to the possibility to retrieve combined information on conformational properties 
and binding state of proteins in heterogeneous mixtures. 
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FIGURE CAPTIONS 
Figure 1. Detection of AS-EGCG complexes by MS. (A) Nano-ESI-MS spectra in positive-ion mode 
IRUDWLWUDWLRQRIȝ0$6E\LQFUHDVLQJ(*&*FRQFHQWUDWLRQV%&0DJQLILFDWLRQRIVHOHFWHGVSHc-
tra (0 and 100 ȝM EGCG) of (A) in the 900-1100 (B) and 1600-2100 (C) m/z regions. The number of 
EGCG molecules bound to AS monomers is indicated by red numbers. Dimer-specific peaks of AS are 
ODEHOHGDV³'´7KHDPPRQLXPDGGXFWRIWKH(*&*GLPHULVODEHOHGDV³'´DOPRVWRYHUODSSHGWR
the 1:1 complex). (D) Deconvolution of selected spectra DQGȝ0(*&*RI (A). (E) Intensity 
of the AS-EGCG complexes (regardless of stoichiometry) for the 8+ and the 15+ ions, relative to the 
total ion intensity of each charge state, as a function of EGCG concentration. Error bars represent the 
standard deviation from three independent experiments. 
 
Figure 2. IM-MS reveals an opposite conformational effect of EGCG and DA binding to AS 
monomers. (A, B) Heat maps of the conformations detected for the 8+ and 15+ charge state of AS, as 
a function of the number of EGCG bound molecules. (C, D) Heat maps of the conformations detected 
for the 11+ and 15+ charge state of AS, as a function of the number of DA bound molecules. C, control 
sample in the absence of the ligand. 
 
Figure 3. Detection of AS-DA complexes by MS. (A) Nano-ESI-MS spectra in positive-ion mode for 
DWLWUDWLRQRIȝ0$6E\LQFUHDVLQJ'$FRQFHQWUDWLRQVAS dimer-VSHFLILFSHDNVDUHODEHOHGDV³'´
The number of DA molecules bound to AS monomers is indicated by red numbers, for selected peaks. 
(B) Deconvoluted spectra of the data reported in (A). (C) Relative intensity of the AS-DA complexes 
(regardless of stoichiometry) versus total ion intensity for each charge state are reported for different 
DA concentrations for the 8+ (compact AS monomers) and 15+ (AS extended conformation) ions. (D) 
Species distribution of AS-DA complexes of distinct stoichiometry as derived from the measurements 
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at 20 µM AS and 6 mM DA. The values calculated according to the 1:3 and 1:4 models, assuming 
identical and independent binding sites, are reported, too. Error bars represent the standard deviation 
from three independent experiments. 
 
Figure 4. Native top-down ETD reveals binding regions for DA and EGCG. Sequence coverage for 
AS in absence (top) and presence of the ligands DA (middle) and EGCG (bottom). Blue brackets 
indicate either c or z fragments without ligand bound, whereas red brackets mark fragments that  
maintain an interaction with the ligand. For DA a well defined binding site within the AS 125YEMPS129 
region was observed, whereas for EGCG a more scattered pattern was observed in line with non-
specific binding. 
 
Figure 5. Model for the mechanism of action by EGCG and DA on AS aggregation. Under normal 
conditions, AS exists as a mixture of several conformational states characterized by different 
compactness. Distinct aggregation pathways may be triggered by environmental factors capable of 
shifting the conformational equilibrium towards peculiar aggregation-prone conformers. EGCG leads 
to the accumulation of complexes with AS in compact conformations, while DA leads to extended 
protein-ligand complexes. The opposite behavior of the two compounds is expected to yield AS 
aggregates with different structural properties and toxicities. 
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